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Abstract
Purpose We conducted a phase I trial of BNP7787 (diso-
dium 2,2-dithio-bis-ethane sulfonate, Tavocept™), a novel
chemoprotective and antitumor enhancing agent adminis-
tered in combination with paclitaxel and cisplatin. The
primary aim was to determine a safe and potentially eYca-
cious BNP7787 dose for preventing and mitigating paclit-
axel- and cisplatin-induced toxicities and to evaluate for
preliminary evidence of eYcacy of treatment.
Patients and methods Twenty-two patients with stage
IIIB/IV non-small cell lung cancer (NSCLC) received
BNP7787 alone 1 week before co-administration of
BNP7787 with paclitaxel followed by cisplatin. Twenty-
one patients were treated with BNP7787 in escalating doses
of 4.1–41.0 g/m2 concurrently with paclitaxel 175 mg/m2
and cisplatin 75 mg/m2 every 3 weeks.
Results The appropriate dose was determined to be
18.4 g/m2 of BNP7787 although no dose-limiting toxicity
was observed up to 41.0 g/m2. Mild intravenous site dis-
comfort, thirst, and nausea were the most common toxici-
ties. One patient developed grade 2 skin rash, which was
severe enough to preclude further study treatment. The
AUC0-inf of the metabolite mesna was approximately 6.3%
of the AUC0-inf of BNP7787. Co-administration of paclit-
axel and cisplatin did not appear to inXuence the pharmaco-
kinetics of BNP7787 and mesna. The overall response rate
was encouraging; 43% including 11 patients with prior che-
motherapy.
Conclusions The recommended dose for phase II/III stud-
ies is 18.4 mg/m2 of BNP7787 in combination with paclit-
axel and cisplatin. Further studies are warranted to assess
whether BNP7787 prevents and mitigates common and
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serious paclitaxel- and cisplatin-related side eVects and
enhances the eYcacy of paclitaxel and cisplatin in
advanced NSCLC patients.
Keywords Chemoprotector · BNP7787 · Mesna · 
Phase I study · Lung cancer
Introduction
Lung cancer is the leading cause of cancer-related deaths in
most industrialized countries. Platinum-containing doublets
have emerged as the standard of care for the Wrst-line treat-
ment of advanced non-small cell lung cancer (NSCLC)
[15]. However, many medical oncologists have not rou-
tinely used cisplatin-based chemotherapy to treat patients
with advanced NSCLC because of serious side eVects, such
as cisplatin nephrotoxicity and other toxicities. Chemotherapy-
induced neuropathy is also a major dose-limiting side eVect
of many commonly used chemotherapeutic agents, includ-
ing platinum drugs and taxanes [10,  23]. Evidence from
randomized controlled trials support that cisplatin-based
doublets result in superior survival advantages over carbo-
platin-based treatment in advanced NSCLC [5, 16].
Disodium 2,2-dithio-bis-ethane sulfonate (BNP7787,
Tavocept™, dimesna) is an investigational new agent that
is being developed as a chemoprotector against cisplatin-
and taxane-induced toxicities and to enhance the antitumor
eVects of chemotherapy [2, 7–9]. BNP7787 is stable and
chemically inert in plasma due to the high PO2 in plasma,
presence of a disulWde linkage, and the absence of enzy-
matic metabolism of disulWdes in plasma [7–9, 20]. In non-
clinical studies, BNP7787 has been observed to distribute
to the kidney, gastrointestinal tract, bone marrow, and neu-
ronal cells, and it is further postulated that a substantial pro-
portion of BNP7787 undergoes non-enzymatic conversion
to mesna, one of its metabolites, as well as mixed disulWdes
which are also pharmacologically active [7–9, 11, 20]. In
preclinical studies, a high concentration of BNP7787 and
active disulWde metabolites as well as mesna that are gener-
ated in the kidney which can provide signiWcant nephropro-
tection mediated by pharmacologically active mixed
disulWdes that inhibit gamma-glutamyl transpeptidase tox-
iWcation, which is postulated to be an underlying major
mechanism of cisplatin renal toxicity [11, 20]. In addition,
BNP7787 administration can provide nephroprotection by
locally inactivating mono-hydrated cisplatin by the forma-
tion of non-toxic thioplatinum complexes [11]. Similar
cytoprotective eVects by BNP7787 have been observed
for toxicities associated with paclitaxel and carboplatin
[4, 8, 9].
Based on the promising preclinical results of BNP7787,
a phase I trial was carried out in patients with advanced
NSCLC. The objectives of this phase I study were (a) to
identify a safe dose of BNP7787 alone and in combination
with cisplatin and paclitaxel; (b) to describe and quantify
the clinical toxicities of BNP7787; (c) to determine the
pharmacokinetics of BNP7787 and one of its active metab-
olites, mesna; and (d) to obtain preliminary evidence of
therapeutic activity in patients with advanced NSCLC.
Patients and methods
GCP compliance
This phase I clinical trial in Japan was conducted in accor-
dance with (1) World Medical Association Declaration of
Helsinki: Recommendations Guiding Medical Doctors in
Biomedical Research Involving Human Subjects (1996),
(2) the Japanese Pharmaceutical AVairs Law and Guide-
lines for Implementation of Clinical Studies for Drugs
(Japanese GCP).
Patient selection
Patients were enrolled in this study if they met all of the
following criteria: histologic or cytologic diagnosis of
NSCLC; no surgery within 2 weeks, no radiotherapy or
chemotherapy within 3 weeks prior to study entry (within
6 weeks for nitrosourea or mitomycin C); a measurable
or evaluable lesion; a performance status of 0 or 1 on the
Eastern Cooperative Oncology Group (ECOG) scale;
adequate bone marrow function (leukocyte count, 4,000–
120,000/L; neutrophil count ¸1,500/L; platelet count
¸100,000/L), normal hepatic function (bilirubin <1.5 £
the upper limit of normal; aspartate amino-transferase
(AST) and alanine amino-transferase (ALT) levels
<2.5 £ the upper limit of normal), and renal function
(creatinine · the upper limit of normal and creatinine
clearance ¸60 mL/min); between 20 and 74 years of age;
written informed consent to the study. Patients were inel-
igible if they had serious infectious diseases or other
severe complications (interstitial pneumonia, uncontrol-
lable diabetes or hypertension); atrial Wbrillation, serious
arrhythmias, or uncontrollable heart failure in previous
6 months; massive pleural or pericardial eVusion; symp-
tomatic brain metastases; active concurrent malignan-
cies; lactating or pregnant women, or those attempting to
become pregnant; men not willing to use contraception;
hearing impairment or neuropathy; had a history of a
drug allergy (alcohol, cremophor, etc.); had other medi-
cal problems severe enough to prevent compliance with
the protocol. The study was approved in advance by the
Institutional Review Board and by the Hospital Ethics
Committee.Cancer Chemother Pharmacol (2011) 67:533–542 535
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Dosage, dose escalation procedure and drug administration
BNP7787 was supplied from BioNumerik Pharmaceuticals,
Inc., San Antonio, TX as a lyophilized powder containing 2
or 10 g of the formulated drug. The starting dose of
BNP7787 was 4.1 g/m2. This starting dose was based on the
analysis and calculation of a BNP7787:cisplatin = 50:1
molar ratio derived from the demonstration of partial cis-
platin nephroprotection in rats and elucidating this important
relationship to formulate and justify a safe starting dose in
humans [7], as well as prior safety data from phase I clinical
trials. Dose escalation steps of BNP7787 in cohorts of at
least three patients each according to the protocol were 8.2,
12.3, 18.4, 27.6, and 41.0 g/m2. The highest dose tested was
justiWed based on prior non-clinical GLP safety studies, and
phase I clinical trials. In the event of dose-limiting toxicity
in one patient at any dose level, a maximum of three addi-
tional patients would be treated. BNP7787 was given as a
single agent by a 30-min intravenous (iv) infusion 1 week
prior to chemotherapy so that pharmacokinetic data on
BNP7787 alone could be collected and compared and again
on day 1. On treatment day 1, paclitaxel dissolved in
500 mL saline was administered intravenously over 3 h at a
dose of 175 mg/m2. Immediately following paclitaxel
administration, the calculated dosage of BNP7787 for the
given dose level (in a minimum volume of 100 mL) was
administered intravenously over 30–45 min, which was
immediately followed by intravenous cisplatin 75 mg/m2 in
500 mL of normal saline administered over 1 h. Study treat-
ment was administered every 3 weeks (one cycle). Prophy-
lactic medications to prevent hypersensitivity reactions to
paclitaxel were administered, including iv dexamethasone
20 mg at 12 and 6 h prior to paclitaxel infusion, and diphen-
hydramine 50 mg po and ranitidine 50 mg iv 30 min before
paclitaxel administration for paclitaxel hypersensitivity pro-
phylaxis. Patients received 1.6 L of normal saline and/or
electrolyte maintenance Xuid prior to BNP7787 administra-
tion. Cisplatin was dissolved and infused along a program of
forced diuresis that included at least 1.0 L of normal saline
and/or electrolyte maintenance Xuid, 300 mL of 20% manni-
tol and furosemide 20 mg iv. Prophylactic antiemetics dur-
ing and after cisplatin administration consisted of
granisetron and dexamethasone.
Patients with evidence of disease progression or those
who experienced intolerable toxicity were removed from
the study treatment.
Pharmacokinetics
Sample collection
A volume of 5 mL sample of blood was obtained immedi-
ately preceding the BNP7787 treatment, 20 min before the
end of the BNP7787 infusion, 10 min before the end of the
BNP7787 infusion, at the end of the infusion, and at 0.25,
0.5, 1.0, 2.0, 4.0, 6.0, and 24 h after infusion 1 week prior
to chemotherapy and day 1 of chemotherapy. The blood
samples were transported to the laboratory on ice. Ethyl-
enediaminetetraacetic acid blood samples were centrifuged
at room temperature for 1 min at 10,000 rpm. Plasma was
separated and immediately deproteinized by adding
methanol. All samples were stored frozen at ¡20°C until
analysis.
LC/MS/MS assay
The samples for pharmacokinetic were shipped on dry ice
to keep the specimens frozen during shipment to the labora-
tory. The total amount of BNP7787 and mesna was
determined by a validated method using liquid chromato-
graphic–tandem mass spectrometry (LC/MS/MS) at Nemoto
Science Co., (Tokyo, Japan; a Finnigan TSQ7000 mass
spectrometer (Thermo Electron Co., USA) equipped with
an electrospray ionization (ESI) source was used for all
measurements. The HPLC separations were performed with
a Waters 2690 Separation module (Waters, Milford, MA,
USA), using a Mightysil RP-18 GP (3.0 £ 150 mm; Kanto
Chemical Co., Tokyo, Japan). The system was operated
using LCQUAN software (version 1.2; Thermo Electron).
The mobile phase was 10 mmol/L ammonium acetate (pH
6.0) at a Xow rate of 0.3 mL/min. The ion transfer capillary
temperature was 25°C, the nitrogen sheath gas Xow rate 80
psi, and the auxiliary gas Xow rate setting 15 units. The
mass spectra were obtained in a selective reaction monitor-
ing (SRM) mode via negative ESI interface within a range
of m/z 141–281 (BNP7787), 81–141 (mesna), respectively.
The lower limit of quantiWcation (LLQ) for BNP7787 and
mesna was 1.00 and 0.10 g/mL, respectively. The intra-
assay precision and accuracy were satisfactory. Precision
was less than 7.1 and 10.0%, accuracy was ranged from
¡7.0 to 3.7% (¡16% at LLQ) and ¡4.2 to 2.0% for
BNP7787 and mesna, respectively. Inter-assay precision
was less than 7.9 and 10.0%, accuracy ranged from ¡10.0
to 7.4% and ¡6.7 to 2.6% for BNP7787 and mesna, respec-
tively. The contribution ratio (r2), calculated using 1/X
weighed regression analysis were higher than 0.99 for both
compounds.
Pharmacokinetic analyses
The following pharmacokinetic parameters of BNP7787
and mesna were estimated using WinNonlin Version 2.1
(Pharsight Corporation, Mountain View, CA). Cmax was the
maximum drug concentration, and Tmax was the elapsed
time to reach Cmax after the intravenous infusion. AUC0-inf
was area under the concentration–time curve calculated by536 Cancer Chemother Pharmacol (2011) 67:533–542
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global summation of the linear trapezoidal rule from time
zero up to the last measurable data point at 24 h post
administration with extrapolation to inWnity. The elimina-
tion rate constant (z) was determined by log-linear regres-
sion analysis of the terminal phase of the plasma
concentration–time curves. The terminal half-life (T1/2) was
calculated by the equation: T1/2 =l n 2 / z. The mean resi-
dence time (MRT) was calculated by the equation of
AUMC (area under the Wrst moment ¡ time curve)/AUC
¡ [infusion time]/2. Clearance (CL) was calculated by
dividing the actual dose received by the AUC. The volume
of distribution at steady state (Vdss) was calculated by the
equation of CL £ MRT.
Evaluation
Tumors were staged based on a complete medical history
and physical examination, routine chest radiography, bone
scintiscanning, computed tomography (CT) of the chest and
abdomen, whole-brain magnetic resonance imaging (MRI)
or CT scan, and Wberoptic bronchoscopy. Staging was per-
formed according to previous TNM criteria [14]. Prior to
the  Wrst course of treatment, a complete blood count
(including a diVerential white cell count and platelet count),
biochemistry tests (including renal function, hepatic func-
tion, and electrolytes), electrocardiogram, and urinalysis
were performed. Complete blood count and biochemistry
tests were repeated at least twice a week after this initial
evaluation, while the other investigations were repeated at
least every 6 weeks to evaluate the target lesions. A com-
plete blood count was repeated every day until recovery,
when ANC <500/l, leukocyte count <1,000/l, or platelet
count <10,000/l was observed during the Wrst cycle of
treatment. Adverse events were recorded and graded using
the National Cancer Institute Common Toxicity Criteria,
Version 2.0. Tumor response was classiWed in accordance
with WHO criteria [13].
Results
Between April 2000 and December 2001, 22 patients par-
ticipated in this trial. Demographics of the study patient
population are shown in Table 1. Seven patients were
women and Wfteen were men, and the median age was
59.5 years (range: 38–74 years) with a median perfor-
mance status of 1. Dosing information is shown in
Table 2. In this study, a total of 74 cycles of BNP7787
were administered. The number of treatment cycles
administered per patient ranged from 1 to 4 (1 cycle in 1
patient, 2 in 4 patients, 3 in 3 patients, and 4 in 14
patients). One patient developed grade 2 skin rash after
Table 1 Patient characteristics
Total no. of patients 22
Sex
Male 15
Female 7
Age: median (range) 59.5 years (38–74)
Performance status (ECOG)
06
11 6
Previous treatment
Chemotherapy 9
Chemotherapy + radiotherapy 2
Surgery 3
Surgery + radiotherapy 1
None 7
No. of prior chemotherapy regimens
Median 1
Range 0–2
Stage
IIIB 4
IV 18
Histology
Adenocarcinoma 15
Squamous cell carcinoma 4
Large cell carcinoma 2
Adenosquamous cell carcinoma 1
Table 2 Dose escalation scheme and treatment administered to patients
Dose level No. of patients BNP7787 Chemotherapy
Dose (g/m2) Total no. of cycles Paclitaxel (mg/m2) Cisplatin (mg/m2) Total no. of cycles
1 3 4.1 10 175 75 7
2 6 8.2 18 175 75 12
3 4 12.3 13 175 75 9
4 3 18.4 12 175 75 9
5 3 27.6 9 175 75 6
6 3 41.0 12 175 75 9Cancer Chemother Pharmacol (2011) 67:533–542 537
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the Wrst course of BNP7787 alone at the level 2; this con-
dition precluded further protocol treatment. A total of 21
patients and 52 cycles of paclitaxel plus cisplatin were
administered (1 cycle in 4 patients, 2 in 3 patients, and 3
in 14 patients). All treated patients were assessed for
BNP7787 toxicity, and 21 patients were assessed for tox-
icity and response to BNP7787 co-administered with pac-
litaxel plus cisplatin.
Toxicities
Side eVects from BNP7787
Generally, toxicities related to BNP7787 administration
were very mild. No grade 2 or worse toxicity was
observed at all dose levels of BNP7787, except for one
instance of grade 2 skin rash observed at dose level 2,
Table 3 Worst toxicities due to single agent BNP7787 administration at all dose levels
Side eVects Dose of BNP7787 (g/m2)
4.1 (n = 3) 8.2 (n = 6) 12.3 (n = 4) 18.4 n = (3) 27.6 (n = 3) 41.0 (n =3 )
Grade Grade Grade Grade Grade Grade
123412341234123412341234
Local iv site discomfort 
(injection site pain and reaction)
000010001000200030003000
T h i r s t 000000000000000000003000
Facial Xush 
(feeling of warmth, Xushing, hot Xush)
000000000000000010003000
S k i n  r a s h 000001000000000010000000
N u m b n e s s 000000000000000010000000
N a u s e a 000000000000000010000000
Vomiting 000000000000000010000000
P a l p i t a t i o n 000000000000000000001000
Nasal obstruction 
(nasal obstruction, rhinitis)
000000000000000000002000
Table 4 Worst toxicities observed at diVerent dose levels of BNP7787 coadministered with paclitaxel and cisplatin
Side eVects Dose of BNP7787 (g/m2)
4.1 (n = 3) 8.2 (n = 5) 12.3 (n = 4) 18.4 n = (3) 27.6 (n = 3) 41.0 (n =3 )
Grade Grade Grade Grade Grade Grade
123412341234123412341234
N e u t r o p e n i a 000200050013001200120003
L e u k o p e n i a 011002302020101011100210
L y m p h o p e n i a 000001000000010001000010
A n e m i a  ( H b  d e c r e a s e d ) 010020000110110001003000
T h r o m b o c y t o p e n i a 100010000000000000000000
N e u t r o p e n i c  f e v e r 000000100000001000100010
N a u s e a 200022100120201012001010
Vomiting 0 1 0 0 0 3 1 0 1 0 2 0001001000000
A n o r e x i a 201012000210201012000210
C o n s t i p a t i o n 000001100010010000000110
G e n e r a l  f a t i g u e 101021001100210020102100
M y a l g i a 000011000010100020001000
A r t h r a l g i a 010022001110210020101100
A l o p e c i a 210012002200020012000300
P e r i p h e r a l  n e u r o p a t h y300040001100200030002000
I n c r e a s e  i n  c r e a t i n i n e 000010000000000000000000538 Cancer Chemother Pharmacol (2011) 67:533–542
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which resulted in cessation of protocol treatment in one
patient (Table 3). The only adverse event encountered at
dose levels 1 through 4 was grade 1 local iv site discom-
fort (injection site pain and reaction) in four of 16
(25.0%) patients. At dose levels 5 and 6, which repre-
sented BNP7787 dose levels of 27.6 and 41.0 g/m2, all
patients experienced transient, reversible grade 1 local
iv site discomfort. At the dose level 5, extension of the
infusion time from 30 to 45 min lessened the injection
site discomfort. At the highest dose level (41.0 g/m2), all
patients received BNP7787 as a 45-min infusion to
lessen the duration, intensity and frequency of injection
site pain, based on prior phase I observations [3, 23].
Despite prolongation of the infusion time, all patients
complained of discomfort of grade 1 at the local iv infu-
sion site. The local iv site discomfort subsided promptly
after completion of the BNP7787 infusion. Other fre-
quently observed BNP7787-related events comprised
facial Xush (4), thirst (3), nasal obstruction (2), nausea
and vomiting (1), and palpitation (1). All these toxicities
were grade 1 and disappeared promptly after the end of
the infusion.
Side eVects from a combination of cisplatin and paclitaxel
Clinically important grade 3/4 non-hematologic toxicities
experienced over all courses of treatment included gastro-
intestinal events of nausea (24% of patients), anorexia
(19%), vomiting (19%), and constipation (14%; Table 4).
General fatigue was noted in 10% of patients. Joint or
muscle pain was reported in 10 or 5%, respectively, of
patients. Grade 2 peripheral neuropathy was reported in
5% of patients. No grade 2 or worse renal toxicity was
observed in this trial.
The principal grade 3/4 hematologic toxicities were neu-
tropenia (95% of patients), leukopenia (43%) and lympho-
penia (5%; Table 4). Grade 3 anemia (5%) was observed.
No grade 3/4 thrombocytopenia was observed in this trial.
Grade 3 neutropenic fever was noted in 19% of patients.
There were no treatment-related deaths during the trial.
There were no signiWcant inXuences of the BNP7787 dose
on the occurrence of these adverse events when compared
to historically similar patients.
Pharmacokinetics
Plasma samples for BNP7787 were obtained from 22
patients who received BNP7787 alone, and from 21
patients who received BNP7787 in combination with pac-
litaxel and cisplatin. The plasma concentration–time
curves for the diVerent doses of BNP7787 are shown in
Fig. 1a, b, and the pharmacokinetic parameters derived
from the plotted data are listed in Tables 5 and 6. The
plasma concentrations of BNP7787 reached the Cmax at the
end of 30–45 min infusion, and it increased proportionally
by the dose. Plasma elimination curves for BNP7787 alone
and in combination with chemotherapy were Wtted using a one-
compartment model with terminal half-life of 0.62–2.33 h and
0.66–1.67 h, with or without chemotherapy, respectively.
Formation of the metabolite mesna was rapidly observed
following administration of the parent compound, and the
mesna Cmax was reached between 0.5 and 1 h after the
end of the BNP7787 infusion. The plasma concentration
of the mesna metabolite decreased more slowly than
that of BNP7787 with the half-life of 0.88–6.45 h and
0.90–6.28 h, respectively (Fig. 2a, b). No signiWcant
diVerences were observed in pharmacokinetic parameters
between BNP7787 alone and in combination with chemo-
therapy. The ratio of Cmax of the metabolite mesna to that
of BNP7787 ranged from 1.4 to 4.2%; this observation is
consistent with prior observations and predicted by the
free thiol hypothesis [9]. The mean AUC0-inf of mesna was
approximately 6.2% of the AUC0-inf of BNP7787. The
observed BNP7787 plasma half-life, Vdss, CL, and MRT
also remained relatively constant over the dose ranges
studied, regardless of chemotherapy administration. The
Fig. 1 Plasma concentration–time curves of BNP7787 in patients receiv-
ing BNP7787 treatment at dose of 4.1 g/m2 (Wlled diamond), 8.2 g/m2
(Wlled square), 12.3 g/m2 ( Wlled triangle), 18.4 g/m2 ( open diamond),
27.6 g/m2 (open square) and 41.0 g/m2 (open circle) in alone (a) and in
combination with paclitaxel and cisplatin (b). Each point represents the
mean of patients. Infusion time was 30 min except for two patients at a
dose level of 27.6 g/m2 and all three patients at dose level of 41.0 g/m2Cancer Chemother Pharmacol (2011) 67:533–542 539
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mean Vdss for BNP7787 alone and in combination
with chemotherapy were 8.45–17.78 and 9.06–21.72,
respectively.
Clinical recommended dose
Following careful review of the phase I trial data from this
and other studies, a BNP7787 dose of 18.4 g/m2 was
selected as the clinically recommended dose based on a bal-
ance of eYcacy and safety observations. The recommended
dose was not based on the maximum tolerated dose since
no dose-limiting toxicities were observed with the adminis-
tration of BNP7787 alone or in combination with chemo-
therapy at any of the dose levels tested.
The selection of 18.4 g/m2 as the recommended phase II
dose was based on the balance of toxicity, higher grades of
neurotoxicity and nephrotoxicity observed with lower
doses of BNP7787 (e.g., 4.1–12.3 g/m2), and the increased
frequency of local IV site discomfort observed at higher
doses of BNP7787 (above 27.6 g/m2).
We also note that the molar ratio of the doses of
BNP7787 18.4 g/m2 and paclitaxel 175 mg/m2 and cisplatin
75 mg/m2 are 275:1 and 226:1, respectively. These molar
ratios of the drugs are consistent with dose molar ratios that
have demonstrated neuroprotection and nephroprotection in
preclinical studies.
Response
Twenty-one patients were assessed for objective tumor
response. Although there was no complete response, nine
patients attained a partial response, with an overall response
rate of 43%. Stable disease was observed in eight patients
(38%). One patient was non-evaluable because of atelectasis
of the lung surrounding and obscuring the primary marker
lesion. The remaining three patients (14%) had progressive
disease. In 10 patients with prior chemotherapy, four (40%)
achieved a partial response. Among 11 patients with no
prior chemotherapy, Wve (46%) had a partial response.
Discussion
This trial demonstrated that administration of BNP7787 at
doses of 4.1 g/m2 up to 41.0 g/m2 alone or in combination
with paclitaxel and cisplatin was safe and feasible. Generally,
Table 5 Pharmacokinetic parameters of BNP7787 after administration of BNP7787 alone and BNP7787 in combination with paclitaxel and cis-
platin
AUC0-t area under the plasma concentration–time curve up to last measurable point at 24 h from infusion, AUC0-inf. area under the plasma concen-
tration–time curve extrapolated to inWnity, Cmax maximum concentration, z elimination rate constant, T1/2 half-life in terminal phase, MRT0-inf.
mean residence time extrapolated to inWnity, Vdss volume of distribution at steady state, CL total body clearance, CT chemotherapy with cisplatin
and paclitaxel
* Values are the no. of patients who received BNP7787 alone/no. of patients who had BNP preceding combination of paclitaxel and cisplatin
** Mean § SD
Parameter Treatment BNP7787 dose (g/m2)
4.1 (n = 3/3)* 8.2 (n = 6/5) 12.3 (n = 4/4) 18.4 (n = 3/3) 27.6 (n = 3/3) 41.0 (n =3 / 3 )
AUC0-t (g·h/mL) BNP alone 499 § 79** 1,332 § 181 1,851 § 485 2,748 § 496 5,576 § 733 8,551 § 948
BNP + CT 453 § 73 1,180 § 194 1,545 § 320 2,552 § 307 5,937 § 2,799 6,577 § 843
AUC0-inf. (g h/mL) BNP alone 501 § 78 1,347 § 194 1,870 § 498 2,757 § 500 5,780 § 981 8,836 § 1,267
BNP + CT 455 § 73 1,194 § 209 1,563 § 330 2,565 § 316 5,974 § 2,774 6,845 § 1,124
Cmax (g/mL) BNP alone 408 § 16 946 § 273 1,176 § 299 1,864 § 127 2,946 § 271 4,233 § 683
BNP + CT 402 § 29 702 § 113 928 § 93 1,627 § 148 2,588 § 672 3,250 § 291
T1/2 (h) BNP alone 0.76 § 0.11 0.92 § 0.19 0.94 § 0.13 0.75 § 0.07 1.19 § 0.43 1.25 § 0.38
BNP + CT 0.72 § 0.09 0.92 § 0.19 0.95 § 0.17 0.78 § 0.16 1.47 § 0.75 1.27 § 0.52
z (h¡1) BNP alone 0.93 § 0.13 0.78 § 0.15 0.75 § 0.11 0.93 § 0.09 0.64 § 0.22 0.59 § 0.17
BNP + CT 0.97 § 0.13 0.78 § 0.13 0.75 § 0.16 0.91 § 0.19 0.54 § 0.22 0.61 § 0.23
MRT0-t (h) BNP alone 0.88 § 0.18 1.18 § 0.22 1.28 § 0.08 1.11 § 0.08 1.46 § 0.28 1.52 § 0.29
BNP + CT 0.83 § 0.13 1.22 § 0.21 1.29 § 0.09 1.21 § 0.19 1.92 § 0.93 1.50 § 0.29
MRT0-inf. (h) BNP alone 0.91 § 0.17 1.24 § 0.28 1.34 § 0.11 1.13 § 0.09 1.67 § 0.52 1.72 § 0.50
BNP + CT 0.86 § 0.13 1.29 § 0.28 1.36 § 0.11 1.24 § 0.21 1.97 § 0.89 1.75 § 0.59
Vdss (L) BNP alone 11.33 § 2.36 11.79 § 2.95 15.37 § 3.34 12.44 § 2.42 13.86 § 1.67 12.19 § 0.92
BNP + CT 11.85 § 2.43 13.53 § 3.45 18.49 § 3.94 14.27 § 0.52 16.52 § 3.52 16.11 § 2.30
CL (L/h) BNP alone 12.57 § 1.84 9.59 § 2.13 11.66 § 3.22 11.20 § 2.94 8.77 § 2.56 7.40 § 1.60
BNP + CT 13.83 § 2.02 10.69 § 2.84 13.70 § 3.29 11.75 § 2.26 9.55 § 4.65 9.71 § 2.65540 Cancer Chemother Pharmacol (2011) 67:533–542
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adverse eVects attributable to BNP7787 were very mild and
reversible. No grade 2 or worse toxicity was observed at all
dose levels, except for grade 2 skin rash observed at dose
level 2, which resulted in termination of study treatment in
that patient (Table 3). The only frequent adverse eVect was
the transient local discomfort at the infusion site of grade 1
up to 18.4 g/m2 of BNP7787. At dose level 5 and 6, which
represented a BNP7787 dose of 27.6 and 41.0 g/m2, all
patients experienced transient local grade 1 discomfort at
the iv site. This toxicity was to some degree, lessened by
extending the infusion time from 30 to 45 min. Other toxic-
ities encountered at these higher dose levels included thirst
(3 of 6 patients), facial Xush (4 of 6 patients), and nasal
obstruction (2 of 6 patients; Table 3). These adverse eVects
usually disappeared promptly after the end of infusion. The
starting dose of 4.1 g/m2 was based on aggregate GLP
safety data in rats and dogs and by the calculation of a
BNP7787:cisplatin = 50:1 molar ratio that was required for
partial cisplatin nephroprotection in rats [7]. Dose-limiting
toxicities were not observed at any dose level, including the
highest tested dose level of 41.0 g/m2 as deWned in the pro-
tocol. This dose level is far in excess for what is required
for cytoprotection in non-clinical studies since the molar
ratio of BNP7787:cisplatin at the BNP7787 41.0 g/m2 dose
level was 503:1. The dose of 41.0 g/m2 of BNP7787 was
well tolerated by NSCLC patients, and the overall safety
proWle in this study is consistent with prior phase I stud-
ies of paclitaxel followed by BNP7787 administered
prior to cisplatin in patients with advanced solid malignan-
cies [3, 19].
BNP7787 pharmacokinetics was similar to those
reported in a previous human phase I study [3, 21]. After
cessation of infusion, the BNP7787 curves showed single-
exponential decay (Fig. 1). In accordance with the report by
Verschraagen et al. [3, 21], with half-life times of 0.66–
1.67 h and 0.62–2.33 h, the concentrations of the BNP7787
alone and in combination with cisplatin and paclitaxel
declined in parallel, with identical slopes (Fig. 1a, b). Mean
BNP7787 Cmax and AUC0-inf increased linearly with dose in
the dose ranges administered (Table 5). Verschraagen et al.
[3, 21] also reported human pharmacokinetics of mesna fol-
lowing administration of IV BNP7787. Mesna formation
following BNP7787 administration observed is consistent
with extravascular non-enzymatic and enzymatic metabo-
lism of BNP7787 [16]. Mesna is reported to be more reac-
tive with hydrated cisplatin when compared with its
disulWde BNP7787 [8,  9,  12,  22]. Mesna appeared in
plasma after the start of BNP7787 infusion, which is con-
sistent with extravascular metabolism and preservation of
the law of mass action balance relationship of disulWde to
Table 6 Pharmacokinetic parameters of mesna following administration of BNP7787 alone and BNP7787 in combination with paclitaxel and
cisplatin
AUC0-t area under the plasma concentration–time curve up to last measurable point, AUC0-inf. area under the plasma concentration–time curve
extrapolated to inWnity, Cmax maximum concentration, Tmax time to maximal concentration, T1/2 half-life in terminal phase, z elimination rate
constant, MRT0-inf. mean residence time extrapolated to inWnity, CT chemotherapy with paclitaxel and cisplatin
* Values are the no. of patients who received BNP alone/no. of patients who had BNP preceding combination of paclitaxel and cisplatin
** Mean § SD
Parameter Treatment BNP7787 dose (g/m2)
4.1 (n = 3/3)* 8.2 (n = 6/5) 12.3 (n = 4/4) 18.4 (n = 3/3) 27.6 (n = 3/3) 41.0 (n =3 / 3 )
AUC0-t (g·h/mL) BNP alone 27.80 § 9.67** 80.92 § 25.01 86.49 § 46.19 163.26 § 71.90 398.21 § 97.95 565.25 § 183.38
BNP + CT 34.75 § 11.50 78.97 § 28.84 85.41 § 22.43 153.19 § 32.24 363.39 § 160.61 421.30 § 153.04
AUC0-inf. (g h/mL) BNP alone 29.33 § 10.14 81.96 § 25.29 88.71 § 45.58 164.97 § 71.13 398.93 § 98.18 566.32 § 183.20
BNP + CT 35.96 § 12.14 80.47 § 28.19 88.59 § 22.42 155.99 § 31.82 364.21 § 161.12 421.81 § 153.04
Cmax (g/mL) BNP alone 10.20 § 0.43 19.84 § 2.37 23.21 § 6.86 47.30 § 13.64 63.22 § 16.25 82.29 § 2.48
BNP + CT 14.55 § 2.44 21.70 § 2.19 24.40 § 4.05 42.15 § 1.91 52.76 § 5.64 62.75 § 4.79
Tmax (h) BNP alone 0.84 § 0.16 1.00 § 0.45 1.25 § 0.28 1.17 § 0.29 1.82 § 0.59 1.69 § 0.95
BNP + CT 0.58 § 0.14 0.90 § 0.14 0.96 § 0.12 1.18 § 0.28 1.82 § 0.60 1.40 § 0.26
T1/2 (h) BNP alone 3.17 § 2.87 4.59 § 0.52 1.74 § 0.95 1.59 § 1.11 2.66 § 0.04 2.70 § 0.21
BNP + CT 2.96 § 2.88 2.96 § 1.56 1.87 § 1.10 1.65 § 1.05 2.75 § 0.10 2.52 § 0.11
z (h¡1) BNP alone 0.36 § 0.26 0.15 § 0.02 0.46 § 0.17 0.57 § 0.29 0.26 § 0.00 0.26 § 0.02
BNP + CT 0.40 § 0.25 0.31 § 0.19 0.44 § 0.17 0.53 § 0.27 0.25 § 0.01 0.27 § 0.01
MRT0-t (h) BNP alone 2.2 § 1.3 3.1 § 0.4 2.3 § 0.8 2.1 § 0.5 3.6 § 0.7 3.8 § 0.7
BNP + CT 1.9 § 0.8 2.6 § 0.9 2.2 § 0.5 2.2 § 0.6 3.7 § 0.8 3.7 § 0.8
MRT0-inf. (h) BNP alone 2.91 § 1.75 3.48 § 0.51 2.48 § 0.71 2.15 § 0.48 3.67 § 0.73 3.86 § 0.72
BNP + CT 2.32 § 1.11 2.91 § 0.88 2.47 § 0.46 2.35 § 0.57 3.77 § 0.78 3.73 § 0.82Cancer Chemother Pharmacol (2011) 67:533–542 541
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thiol in plasma under physiological conditions [9]. The
metabolite-to-BNP7787 ratio of Cmax was about 2.2%,
which is predicted by the free thiol hypothesis and prior
studies [9]. Although plasma concentrations of BNP7787
began to decline at the end of the infusion, those of the
metabolite increased initially and the maximal plasma lev-
els were reached from 30 min to 1 h after the end of the
infusion, with the half-life of from 0.88 to 6.45 h and from
0.90 to 6.28 h for BNP7787 alone and in combination with
chemotherapy, respectively. The administration of paclit-
axel and cisplatin in this study did not show any observable
eVect on BNP7787 pharmacokinetics when compared to
the observed pharmacokinetics of single agent administra-
tion of BNP7787. This observation further supports prior
studies demonstrating that BNP7787 is compatible and fea-
sible with regard to co-administration of paclitaxel and cis-
platin when all drugs are administered on this schedule and
by the iv route (Table 5) [3, 7–9, 11, 20].
Of 21 patients, the overall response rate of 43% was
observed during this phase I trial in patients with advanced
NSCLC although no patients showed a complete response.
The combination of paclitaxel and cisplatin in advanced
NSCLC patients with no prior chemotherapy is historically
reported to produce response rates between 21 and 41%
[1,  6,  16–18]. A response rate of 46% in previously
untreated patients observed here appears to be in the upper
range of the reported trials in NSCLC with this regimen,
and the co-administration of BNP7787 did not appear to
interfere with the antitumor activity of paclitaxel and cis-
platin in patients with advanced NSCLC. It is notable that
four of 10 patients (40%) patients attained a PR in patients
who had received prior chemotherapy, supporting further
evaluation of BNP7787 in additional clinical studies. The
number of patients in this study is too small to draw any
valid conclusion about the ultimate clinical activity of this
regimen, and it will be investigated in future studies.
In conclusion, this study conWrmed that administration
of a recommended BNP7787 dose level of 18.4 g/m2 in
combination with paclitaxel and cisplatin is safe to use to
evaluate for potential eYcacy in future studies in patients.
The more common and non-dose-limiting BNP7787-
related toxicities included local transient discomfort at the
infusion site, facial Xush, thirst, and nasal obstruction were
very mild, and usually not greater than grade 2. A random-
ized multicenter phase III trial of paclitaxel, BNP7787 and
cisplatin was subsequently initiated to determine the safety
and eYcacy of BNP7787 for the prevention of paclitaxel-
and cisplatin-induced neurotoxicity, as well as other toxici-
ties and also to evaluate the potential eYcacy of BNP7787
in patients with advanced NSCLC.
Acknowledgments We acknowledge Ms. Erika Ramirez at
BioNumerik Pharmaceuticals Inc. for her skillful editorial assistance in
the preparation of this manuscript.
ConXict of interest statement Frederick Hausheer, MD, FACP, is a
signiWcant shareholder in BioNumerik Pharmaceuticals Inc. the origi-
nator of Tavocept, and is in a leadership and management position in
this company. The funding source of this trial is ASKA Pharmaceuti-
cals Co., which is in a Joint Venture relationship with BioNumerik
Pharmaceuticals Inc. in Japan. Other authors indicated no potential
conXicts of interest.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
References
1. Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E,
Jiroutek M, Johnson D (2000) Comparison of survival and quality
of life in advanced non-small-cell lung cancer patients treated with
two dose levels of paclitaxel combined with cisplatin versus eto-
poside with cisplatin: results of an Eastern Cooperative Oncology
Group trial. J Clin Oncol 18:623–631
Fig. 2 Plasma concentration–time curves of the active metabolite,
mesna in patients receiving BNP7787 treatment at dose of 4.1 g/m2
(Wlled diamond), 8.2 g/m2 (Wlled square), 12.3 g/m2 (Wlled triangle),
18.4 g/m2 (open diamond), 27.6 g/m2 (open square) and 41.0 g/m2
(open circle) in alone (a) and in combination with paclitaxel and
cisplatin (b). Each point represents the mean of patients. Infusion
time was 30 min except for three patients at the highest dose level of
41.0 g/m2542 Cancer Chemother Pharmacol (2011) 67:533–542
123
2. Boven E, Verschraagen M, Hulscher TM, Erkelens CA, Hausheer
FH, Pinedo HM, van der Vijgh WJ (2002) BNP7787, a novel pro-
tector against platinum-related toxicities, does not aVect the eY-
cacy of cisplatin or carboplatin in human tumour xenografts. Eur J
Cancer 38:1148–1156
3. Boven E, Westerman M, van Groeningen CJ, Verschraagen M,
Ruijter R, Zegers I, van der Vijgh WJ, Giaccone G (2005) Phase I
and pharmacokinetic study of the novel chemoprotector BNP7787
in combination with cisplatin and attempt to eliminate the hydra-
tion schedule. Br J Cancer 92:1636–1643
4. Cavalletti E, Cavaletti G, Tredici G, Oggioni N, Spinelli S, Reddy
D, Zhao M, Wu M, Hauseheer F (1999) Oral and intravenous
BNP7787 protects against paclitaxel-mediated neurotoxicity in
Wistar rats. Proc Am Soc Cancer Res 40:398
5. Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V,
Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward
M, Belani CP (2003) Randomized, multinational, phase III study
of docetaxel plus platinum combinations versus vinorelbine plus
cisplatin for advanced non-small-cell lung cancer: the TAX 326
study group. J Clin Oncol 21:3016–3024
6. Giaccone G, Splinter TA, Debruyne C, Kho GS, Lianes P, van
Zandwijk N, Pennucci MC, Scagliotti G, van Meerbeeck J, van
Hoesel Q, Curran D, Sahmoud T, Postmus PE (1998) Randomized
study of paclitaxel-cisplatin versus cisplatin-teniposide in patients
with advanced non-small-cell lung cancer. The European
Organization for Research and Treatment of Cancer Lung Cancer
Cooperative Group. J Clin Oncol 16:2133–2141
7. Hausheer FH, Kanter P, Cao S, Haridas K, Seetharamulu P,
Reddy D, Petluru P, Zhao M, Murali D, Saxe JD, Yao S, Martinez
N, Zukowski A, Rustum YM (1998) Modulation of platinum-in-
duced toxicities and therapeutic index: mechanistic insights and
Wrst- and second-generation protecting agents. Semin Oncol
25:584–599
8. Hausheer FH, Kanter P, Rustum Y, Cao S, Haridas K, Reddy D,
Seetharamulu P, Zhao M, Yao S, Pavankumar P, Murali D (2001)
BNP7787: a novel antitumor potentiating drug which protects
against cisplatin and carboplatin toxicities. Proc Am Soc Cancer
Res 38:311
9. Hausheer FH, Kochat H, Parker AR, Ding D, Yao S, Hamilton SE,
Petluru PN, Leverett BD, Bain SH, Saxe JD (2003) New approach-
es to drug discovery and development: a mechanism-based
approach to pharmaceutical research and its application to
BNP7787, a novel chemoprotective agent. Cancer Chemother
Pharmacol 52(Suppl 1):S3–S15
10. Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F
(2006) Diagnosis, management, and evaluation of chemotherapy-
induced peripheral neuropathy. Semin Oncol 33:15–49
11. Hausheer FH, Shanmugarajah D, Leverett BD, Chen X, Huang Q,
Kochat H, Petluru PN, Parker AR (2010) Mechanistic study of
BNP7787-mediated cisplatin nephroprotection: modulation of
gamma-glutamyl transpeptidase. Cancer Chemother Pharmacol
65:941–951
12. Leeuwenkamp OR, Neijt JP, van der Vijgh WJ, Pinedo HM (1991)
Reaction kinetics of cisplatin and its monoaquated species with the
modulating agents (di)mesna and thiosulphate. Eur J Cancer
27:1243–1247
13. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Report-
ing results of cancer treatment. Cancer 47:207–214
14. Mountain CF (1997) Revisions in the international system for
staging lung cancer. Chest 111:1710–1717
15. PWster DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S
Jr, Olak J, Stover D, Strawn JR, Turrisi AT, SomerWeld MR (2004)
American Society of Clinical Oncology treatment of unresectable
non-small-cell lung cancer guideline: update 2003. J Clin Oncol
22:330–353
16. Rosell R, Gatzemeier U, Betticher DC, Keppler U, Macha HN,
Pirker R, Berthet P, Breau JL, Lianes P, Nicholson M, Ardizzoni
A, Chemaissani A, Bogaerts J, Gallant G (2002) Phase III random-
ised trial comparing paclitaxel/carboplatin with paclitaxel/cis-
platin in patients with advanced non-small-cell lung cancer: a
cooperative multinational trial. Ann Oncol 13:1539–1549
17. Sakai H, Yoneda S, Tamura T, Nishiwaki Y, Yokoyama A,
Watanabe K, Saijo N (2001) A phase II study of paclitaxel plus
cisplatin for advanced non-small-cell lung cancer in Japanese
patients. Cancer Chemother Pharmacol 48:499–503
18. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J,
Zhu J, Johnson DH (2002) Comparison of four chemotherapy reg-
imens for advanced non-small-cell lung cancer. N Engl J Med
346:92–98
19. Schilsky RL, Desai A, Creaven P, Berghorn E, Ratain M, Hauseh-
eer F (2003) BNP7787 permits safe administration of paclitaxel
and cisplatin without iv hydration. Proc Am Soc Clin Oncol
22:594
20. Shanmugarajah D, Ding D, Huang Q, Chen X, Kochat H, Petluru
PN, Ayala PY, Parker AR, Hausheer FH (2009) Analysis of
BNP7787 thiol-disulWde exchange reactions in phosphate buVer
and human plasma using microscale electrochemical high perfor-
mance liquid chromatography. J Chromatogr B Analyt Technol
Biomed Life Sci 877:857–866
21. Verschraagen M, Boven E, Ruijter R, van der Born K, Berkhof J,
Hausheer FH, van der Vijgh WJ (2003) Pharmacokinetics and
preliminary clinical data of the novel chemoprotectant BNP7787
and cisplatin and their metabolites. Clin Pharmacol Ther 74:157–
169
22. Verschraagen M, Kedde MA, Hausheer FH, Van Der Vijgh WJ
(2003) The chemical reactivity of BNP7787 and its metabolite
mesna with the cytostatic agent cisplatin: comparison with the
nucleophiles thiosulfate, DDTC, glutathione and its disulWde
GSSG. Cancer Chemother Pharmacol 51:499–504
23. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C (2008)
Chemotherapy-induced peripheral neuropathy: prevention and
treatment strategies. Eur J Cancer 44:1507–1515